In patients with melanoma and confirmed progression on a PD-1, lenvatinib plus pembrolizumab demonstrated clinically meaningful responses.
Rates of relapse-free and overall survival were high as well, exceeding 90%.
Patients were more likely to benefit from pembrolizumab if they had not previously received the drug.
Pembrolizumab bested high-dose interferon alfa-2b and high-dose ipilimumab.
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Lifileucel has produced responses lasting more than 2 years in patients with limited treatment options.
This is the first phase 3 study to validate LAG-3 inhibition as a therapeutic strategy in cancer, according to an investigator.
Therapeutic combinations of immune checkpoint blockade with targeted, oncolytic, or antiangiogenic approaches are promising for patients with cutaneous melanoma.
Researchers findings support the use of pembrolizumab in patients with resected stage III melanoma.
Changes 2 to 4 months after the start of therapy with pembrolizumab may predict long-term response and survival.
Gene expression analysis and the identification of a single gene or a signature correlated with patients’ outcomes could lead to improved patient stratification.
TCI use also resulted in an increased risk of lymphoma in the 3 studies with topical corticosteroid comparators.
Researchers found that low grade irAEs after anti-PD-1 therapy were more common than previously reported and frequently persist after prolonged follow-up.
Melanoma excised with Mohs micrographic surgery, those treated at academic and higher-volume facilities had improved long-term survival.
Because of immunosuppressive therapy following liver transplantation, de novo malignancies can occur, and the most common are skin cancers.
Among patients younger than 49 years, those with actinic keratosis had a nearly 7-times greater likelihood of developing cutaneous squamous cell carcinoma than patients without actinic keratosis.
A team of investigators sought to assess the impact of multimodality, CNS-directed treatments on survival rates in patients with melanoma brain metastasis.
Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
A team of investigators created the myeloid index score, which captures the prognostic value of blood myeloid cells and may be used in the management of patients with melanoma.
A team of international researchers sought to confirm a “dual pathway hypothesis” for the development of melanoma.